miRNA药物的发展前景

摘要/Abstract

摘要： microRNA（miRNA）是一类非编码RNA（ncRNA），在转录后水平调节内源性基因表达。miRNA通过直接或间接上调或下调靶标mRNA的表达,几乎参与体内所有生理和病理过程。miRNA具有易于化学合成和修饰的优点，使其成为具有巨大治疗潜力的主要非编码RNA。本研究梳理miRNA类似物和抑制剂在癌症、心血管疾病、代谢性疾病等领域的的治疗靶点及作用机制，总结miRNA类似物和抑制剂的临床试验进展及优势，讨论miRNA药物治疗的机制、进展和存在的RNA稳定性和递送瓶颈问题及解决方案。尽管目前miRNA药物的发展尚存在一些挑战，但miRNA仍然是制药业中前景光明的靶标。

关键词: font-size:medium, ">非编码RNA；miRNA；miRNA模拟物；miRNA抑制剂

Abstract: MicroRNA(miRNA) are a class of non-coding RNAs that regulate endogenous gene expression at the post-transcriptional level. It actively participates in almost all physiological and pathogenetic processes in vivo， through upregulating or downregulating the expression of target messenger RNA. The merits of easy chemical synthesis and modification make miRNA the major class of noncoding RNA with great therapeutical potential. In this artical，the miRNA drug researches in the fields of cancer， cardiovascular diseases， metabolic diseases， as well as the treatment principles and strategies were reviewed. The progresses of ongoing clinical trials of miRNA analogues and inhibitors were summarized. The mechanism， progress and challenges of the miRNA therapy were discussed. Despite the existing of some technical bottlenecks， miRNAs still remain as one of the promising therapeutical targets in the pharmaceutical industry.

Key words: font-size:medium, ">Non-coding RNA； miRNA； MiRNA mimics； MiRNA inhibitors

中图分类号:

徐博扬, 胡长龙. miRNA药物的发展前景[J]. 中国医药导刊, 2022, 24(2): 122-126.

XU Boyang, HU Changlong. Perspective of MiRNA Drugs[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(2): 122-126.

参考文献

[1]Lee RC， Feinbaum RL，Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 [J]. Cell， 1993， 75(5):843-854.
     [2]Toden S， Zumwalt TJ， Goel A. Non-coding RNAs and potential therapeutic targeting in cancer [J]. Biochim Biophys Acta Rev Cancer， 2021， 1875(1):188491.
     [3]Esteller M. Non-coding RNAs in human disease [J]. Nat Rev Genet， 2011， 12(12):861-874.
     [4]Ha M，Kim VN. Regulation of microRNA biogenesis [J]. Nat Rev Mol Cell Biol， 2014， 15(8):509-524.
     [5]Sung H， Ferlay J， Siegel RL， et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin， 2021， 71(3):209-249.
     [6]Cuciniello R， Filosa S，Crispi S. Novel approaches in cancer treatment:preclinical and clinical development of small non-coding RNA therapeutics [J]. J Exp Clin Cancer Res， 2021， 40(1):383.
     [7]Wang J， Dan G， Zhao J， et al. The predictive effect of overexpressed miR-34a on good survival of cancer patients:a systematic review and meta-analysis [J]. Onco Targets Ther， 2015， 8:2709-2719.
     [8]Daige CL， Wiggins JF， Priddy L， et al. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer [J]. Mol Cancer Ther， 2014， 13(10):2352-2360.
     [9]Hong DS， Kang YK， Borad M， et al. Phase 1 study of MRX34， a liposomal miR-34a mimic， in patients with advanced solid tumours [J]. Br J Cancer， 2020， 122(11):1630-1637.
     [10]Pekarsky Y，Croce CM. Role of miR-15/16 in CLL [J]. Cell Death Differ， 2015， 22(1):6-11.
     [11]Reid G， Kao SC，Pavlakis N，et al. Clinical development of TargomiRs， a miRNA mimic-based treatment for patients with recurrent thoracic cancer [J]. Epigenomics， 2016， 8(8):1079-1085.
     [12]Cavallari I， Ciccarese F， Sharova E， et al. The miR-200 family of microRNAs:fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers [J]. Cancers (Basel)， 2021， 13(23):5874.
     [13]Xu H， Luo M， Xiang H， et al. miR-506-3p can inhibit cell proliferation and is a diagnostic and prognostic marker of liver cancer [J]. Am J Transl Res， 2021， 13(10):11531-11539.
     [14]Keklikoglou I，Koerner C，Schmidt C，et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways [J]. Oncogene， 2012， 31(37):4150-4163.
     [15]Kota J，Chivukula RR，O′Donnell KA，et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model [J].Cell， 2009， 137(6):1005-1017.
     [16]Seto AG，Beatty X，Lynch JM， et al. Cobomarsen， an oligonucleotide inhibitor of miR-155， co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma [J].Br J Haematol，2018，183(3):428-444.
     [17]Witten L，Slack FJ. miR-155 as a novel clinical target for hematological malignancies [J]. Carcinogenesis， 2020， 41(1):2-7.
     [18]Sheedy P，Medarova Z.The fundamental role of miR-10b in metastatic cancer [J].Am J Cancer Res， 2018， 8(9):1674-1688.
     [19]Bautista-Sanchez D，Arriaga-Canon C，Pedroza-Torres A，et al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics [J]. Mol Ther Nucleic Acids， 2020， 20:409-420.
     [20]Park JK，Kogure T，Nuovo GJ，et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival [J].Cancer Res，2011，71(24):7608-7616.
     [21]Huang CK，Kafert-Kasting S，Thum T. Preclinical and clinical development of noncoding RNA therapeutics for cardiovascular disease [J].Circ Res，2020，126(5):663-678.
     [22]Das S，Mohamed IN，Teoh SL， et al. Micro-RNA and the features of metabolic syndrome:anarrative review [J].Mini Rev Med Chem，2020，20(7):626-635.
     [23]Wang X，He Y，Mackowiak B， et al. MicroRNAs as regulators， biomarkers and therapeutic targets in liver diseases [J].Gut，2021， 70(4):784-795.
     [24]Rupaimoole R，Slack FJ. MicroRNA therapeutics：towards a new era for the management of cancer and other diseases [J]. Nat Rev Drug Discov，2017， 16(3):203-222.
     [25]Levin AA. Treating disease at the RNA level with oligonucleotides [J]. N Engl J Med，2019， 380(1):57-70.
     [26]Finan C，Gaulton A，Kruger FA， et al. The druggable genome and support for target identification and validation in drug development [J]. Sci Transl Med， 2017， 9(383):1166.
     [27]Lucas T， Bonauer A，Dimmeler S. RNA therapeutics in cardiovascular disease [J]. Circ Res， 2018， 123(2):205-220.
     [28]Yin W， Rogge M. Targeting RNA:atransformative therapeutic strategy [J]. Clin Transl Sci， 2019， 12(2):98-112.
     [29]Forterre A， Komuro H， Aminova S， et al. A comprehensive review of cancer microRNA therapeutic delivery strategies [J]. Cancers (Basel)， 2020， 12(7):1852.
     [30]Adams BD， Parsons C， Walker L， et al. Targeting noncoding RNAs in disease [J]. J Clin Invest， 2017， 127(3):761-771.

快速检索引用检索图表检索高级检索